Dehydrocorydaline (hydroxyl)

Dehydrocorydaline (hydroxyl)

• UNSPSC Description: Dehydrocorydaline (13-Methylpalmatine) hydroxyl is an alkaloid that regulates protein expression of Bax, Bcl-2; activates caspase-7, caspase-8, and inactivates PARP. Dehydrocorydaline hydroxyl elevates p38 MAPK activation. Anti-inflammatory and anti-cancer activities. Dehydrocorydaline hydroxyl shows strong anti-malarial effects (IC50=38 nM), and low cytotoxicity (cell viability > 90%) using P. falciparum 3D7 strain.
• Target Antigen: Autophagy; Bcl-2 Family; Caspase; p38 MAPK; Parasite; PARP
• Type: Natural Products
• Related Pathways: Anti-infection;Apoptosis;Autophagy;Cell Cycle/DNA Damage;Epigenetics;MAPK/ERK Pathway
• Applications: COVID-19-anti-virus
• Field of Research: Cancer; Infection; Inflammation/Immunology
• Assay Protocol: https://www.medchemexpress.com/dehydrocorydaline-hydroxyl.html
• Purity: 99.52
• Solubility: DMSO : 12.5 mg/mL (ultrasonic;warming;heat to 60°C)
• Smiles: CC1=C(C=CC(OC)=C2OC)C2=C[N+]3=C1C4=CC(OC)=C(OC)C=C4CC3.[OH-]
• Molecular Weight: 383.44
• References & Citations: [1]Xu Z, et al. Dehydrocorydaline inhibits breast cancer cells proliferation by inducing apoptosis in MCF-7 cells. Am J Chin Med. 2012;40(1):177-85.|[2]Yoo M, et al. Dehydrocorydaline promotes myogenic differentiation via p38 MAPK activation. Mol Med Rep. 2016 Oct;14(4):3029-36.|[3]Nonaka M, et al. Screening of a library of traditional Chinese medicines to identify anti-malarial compounds and extracts. Malar J. 2018 Jun 25;17(1):244.|[4]Yin ZY, et al. Antinociceptive effects of dehydrocorydaline in mouse models of inflammatory pain involve the opioid receptor and inflammatory cytokines. Sci Rep. 2016 Jun 7;6:27129.Int J Biol Macromol. 2024 May;266(Pt 1):130939.|Aging (Albany NY). 2021 Oct 7;13(19):23133-23148.|Aging. 2021 May 11;13(9):12780-12799.|Biochem Biophys Res Commun. 2018 May 23;499(4):743-750. |Biochem Biophys Res Commun. 2018 Sep 5;503(2):467-473. |Biochem Pharmacol. 2024 Oct 11:116574.|BMC Musculoskelet Disord. 2022 May 30;23(1):514.|Bone Joint Res. 2023 Nov 1;12(11):677-690.|Comput Math Methods Med. 2021 Aug 2;2021:3337514.|Eur J Pharmacol. 2021 Mar 31;174069.|Infect Genet Evol. 2021 Nov 23;105158.|J Agric Food Chem. 2023 Oct 12.|J Cell Physiol. 2019 Dec;234(12):22463-22476.|J Clin Neurosci. 2020 Aug;78:365-370.|J Mol Histol. 2021 Feb 8.|J Nutr. 2020 Jul 1;150(7):1731-1737.|Mol Carcinog. 2024 Aug 13.|Bioengineered. 2022 May;13(5):12847-12862.|Exp Eye Res. 2022 Dec 25;109365.|Front Pharmacol. 31 May 2021.|Int Immunopharmacol. 2024 Jul 23:139:112720.|J Clin Invest. 2024 Jun 18:e178303.|J Ethnopharmacol. 2024 Aug 31:118738.|J Inflamm Res. 2021 Sep 16;14:4669-4686.|New Phytol. 2024 May 13.|Phytomedicine. 8 September 2021, 153740.|Tissue Cell. 2023 Sep 11, 102218.|Research Square Preprint. 2020 Dec.
• Shipping Conditions: Room Temperature
• Storage Conditions: -20°C, 3 years; 4°C, 2 years (Powder)
• Clinical Information: No Development Reported